Koers Altimmune Inc Nyse
Aandelen
US71714G1022
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
23/05 | Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM | |
09/05 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Omzet 2024 * | 31,25 mln. 28,82 mln. | Omzet 2025 * | 25 mln. 23,05 mln. | Marktkapitalisatie | 520 mln. 479 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -59 mln. -54,4 mln. | Nettowinst (verlies) 2025 * | -142 mln. -131 mln. | EV/omzet 2024 * | 14,6 x |
Nettoliquiditeiten 2024 * | 63,88 mln. 58,91 mln. | Nettoliquiditeiten 2025 * | 257 mln. 237 mln. | EV/omzet 2025 * | 10,5 x |
K/w-verhouding 2024 * |
-8,71
x | K/w-verhouding 2025 * |
-5,82
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,22% |
Recentste transcriptie over Altimmune Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 30-11-18 |
Director of Finance/CFO | 66 | 31-12-21 | |
Anthony Blandin
CMP | Compliance Officer | - | 01-02-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 01-04-10 |
Mack Gill
BRD | Director/Board Member | 72 | 01-08-04 |
Philip Hodges
BRD | Director/Board Member | 56 | 01-09-03 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,30% | 118 mld. | |
+12,15% | 106 mld. | |
-8,14% | 23,4 mld. | |
-1,69% | 21,78 mld. | |
-10,60% | 18,09 mld. | |
-41,25% | 16,72 mld. | |
-15,33% | 15,97 mld. | |
+5,80% | 14,03 mld. | |
+28,03% | 11,67 mld. |